Renal Cell Carcinoma (RCC) – Rana McKay, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GU 2019

Renal Cell Carcinoma (RCC) – Rana McKay, MD, and Robert Figlin, MD, discuss clinical highlights from ASCO GU 2019

Tuesday March 5, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Rana McKay, Assistant Professor of Medicine, University of California San Diego, discuss renal cell carcinoma (RCC) clinical highlights from ASCO GU 2019

Non Small Cell Lung Cancer (NSCLC) – Edward Garon, MD, and Robert Figlin, MD, discuss promising agents in development for the management of NSCLC from ASCO20

Thursday June 11, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Waldenstrom macroglobulinemia – Constantine Tam, MD, and Robert Figlin, MD, discuss recent clinical advances in the treatment of Waldenstrom macroglobulinemia from ASCO20

Monday June 8, 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20

Featured Videos

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

Shaji Kumar, MD, discusses excitement about bispecific antibodies in multiple myeloma